Bio-Rad Laboratories, Inc.Class A vs. Revvity, Inc.
Bio-Rad Laboratories, Inc.Class A and Revvity, Inc. are evenly matched on the factors we track — the better pick depends on what you're optimizing for.
Size & Scale
| BIO | RVTY | |
|---|---|---|
| Market Cap | $10.06 billion | $16.01 billion |
| Revenue (TTM) | $2.59 billion | — |
| Net Income (TTM) | $222.40 million | — |
RVTY leads on 1 of 1 size & scale factors.
Valuation
| BIO | RVTY | |
|---|---|---|
| P/E Ratio | 45.85 | — |
| Price / Book | 1.40 | — |
| Price / Sales | 3.89 | — |
BIO and RVTY split the valuation factors evenly.
Profitability
| BIO | RVTY | |
|---|---|---|
| Net Margin | 8.59% | — |
| Return on Equity | 3.10% | — |
BIO and RVTY split the profitability factors evenly.
Dividend
| BIO | RVTY | |
|---|---|---|
| Dividend Yield | — | 0.20% |
BIO and RVTY split the dividend factors evenly.
Risk & Sentiment
| BIO | RVTY | |
|---|---|---|
| Short Interest | 2.44% | 2.98% |
BIO leads on 1 of 1 risk & sentiment factors.
Dig deeper: BIO overview, BIO financials, RVTY overview, RVTY financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.